Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 gl-1), recombinant human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial dose was 50 Units Kg-1 of body weight. If response was not achieved within 3 weeks, dose was incre...
Main Authors: | , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
1993
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968216/ |